POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).						
I hereby appoint:						
X P	X Practitioners associated with the Customer Number: 78018					
OR						
Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):						
	Ņame	Registration Number	egistration Name Number		Registration Number	
					, , , , , , , , , , , , , , , , , , , ,	
	***************************************		•			
-		Ŷ.				
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).						
Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:						
The address associated with Customer Number: 78018						
OR						
Firm or Individual Name						
Address .						
City		State	State		Zip	
Countr	ountry					
	Telephone Email					
Liciopii						
Assignee Name and Address:						
Novartis AG						
Basel, Switzerland						
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be						
filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of						
the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must Identify the application in which this Power of Attorney is to be filed.						
SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignee						
Signatur	e /Dean Nakamura,	/	Da	te 5 Februar	y 2009	
Name	Dean Nakamura	0004705005			986	
Title						
T1.1	······································	24 4 22 and 4 22. The information		- bearfithe the mobile of	ab is to file land	

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to lake 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)						
Applicant/Patent Owner: Novartis AG						
Application No./Patent No.: 10529428 Filed/Issue	Date: 9 November 2006					
Entitled: Potassium channel mutants of the yeast Saccharomyces cerevisiaeeukaryotic potassium channels						
Novartis AG , a corpora	tionsignee, e.g., corporation, partnership, university, government agency, etc.)					
(Name of Assignee) (Type of Assignee)	ssignee, e.g., corporation, partnership, university, government agency, etc.)					
states that it is: 1. the assignee of the entire right, title, and interest; or						
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)						
in the patent application/patent identified above by virtue of either:						
A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.						
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:						
From: To: The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.						
2. From:To:						
The document was recorded in the United States Pa	tent and Trademark Office at or for which a copy thereof is attached.					
From: To: To: The document was recorded in the United States Pa						
The document was recorded in the United States Pa	tent and Trademark Office at					
Reel, Frame, or for which a copy thereof is attached.						
Additional documents in the chain of title are listed on a supplemental sheet.						
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.						
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]						
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.						
/Dean Nakamura/	9 February 2009					
Signature	Date					
Dean Nakamura, Reg. No. 33981	202.412.6986					
Printed or Typed Name	Telephone Number					
Agent/Attorney Title						

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

Attorney Docket No.: 010804-22190200

WHEREAS <u>Peter Anthony CAMPOCHIARO and Michael KALEKO</u>, hereinafter referred to as the Assignors, have invented a certain improvement relating to <u>OCULAR</u> <u>GENE THERAPY</u>, which said Assignors have caused an application for United States Letters Patent to be prepared, said application having been filed in the United States Patent and Trademark Office on <u>25 March 2005</u>, having serial number <u>10/529,428</u>, which arose from PCT Ser. No. <u>EP2003/010725</u> filed <u>28 September 2003</u>, which claims benefit to U.S. Ser. No. <u>60/414,048</u> filed <u>27 September 2002</u>;

WHEREAS <u>NOVARTIS AG</u>, <u>Lichstrasse 35</u>, <u>CH-4056 Basel</u> hereinafter referred to as the Assignee, is desirous of acquiring the entire right, title and interest in and to said applications, including any and all divisions and continuations thereof, and in and to said invention and any and all patents which may be granted therefore, including any and all renewals, reissues, parental applications and prolongations thereof;

NOW, WITNESSETH, that for and in consideration of One Dollar (\$1.00), and other good and valuable consideration paid by Assignee to Assignors, the receipt and sufficiency of which is hereby acknowledged, Assignors, nunc pro tunc, hereby assign, sell and transfer, and has assigned, sold, and transferred to Assignee, its successors and assigns, the entire and exclusive right, title, and interest for the United States in and to the invention, the US application, the PCT application and the provisional application (noted above), and any patents which may be granted therefor, including any and all divisions, continuations, in whole or in part, substitutions, renewals, reissues, reexaminations, and extensions thereof, and all applications claiming priority therefrom; and Assignor authorizes and requests the Commissioner of Patents and Trademarks to issue all patents for the invention, or patents resulting therefrom, insofar as their interest is concerned, to Assignee; to have, hold, exercise, and enjoy, with all the rights, powers, privileges, and advantages in anywise arising therefrom or appertaining thereto, for and during the term or terms of any and all such patents when granted, for the use and benefit of said Assignee, and said successors and assigns of said Assignee, in as ample and beneficial a manner as Assignors might or could have held and enjoyed the same, if this assignment had not been made.

Assignors further, nunc pro tunc, hereby assign, sell and transfer, and have assigned, sold, and transferred to Assignee, its successors and assigns, the entire right, title and interest in all countries of the world, in and to the invention and in and to the application and the parental applications noted herein, and all patents which may be granted therefor, and all national applications, regional applications, divisions, reissues, substitutions, continuations, in whole or in part, re-examinations, and extensions thereof, including the right to file applications and obtain patents for the invention in its own name, in all countries and including all rights of priority in all countries under the terms of any applicable international convention, insofar as its interest is concerned; and the Assignors hereby authorize and request the applicable patent office in each country of the world to issue all patents for the invention, or patents resulting thereform, insofar as its interest is

ASSIGNMENT

Page 2

concerned, to the Assignee, to have and to hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for which any and all of such patents for the invention may issue, to the same extent as the Assignors would hold and enjoy if this Assignment had not been made.

The Assignors further agree to execute any and all patent applications, assignments, affidavits, and any other papers in connection therewith necessary to perfect such patent rights, and also agree, at the request of the Assignee, to testify in any legal proceedings, sign all lawful papers, make all lawful oaths, and generally do everything possible to aid said Assignee, its successors and assigns, to obtain, maintain and enforce proper patent protection for said invention.

Signature: Name:

Date:

Signature:

Name: Date:

01518044